Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2000 Dec;91(12):1339–1344. doi: 10.1111/j.1349-7006.2000.tb00923.x

Oncolytic Viral Therapy for Human Prostate Cancer by Conditionally Replicating Herpes Simplex Virus 1 Vector G207

Masafumi Oyama 1,2, Takashi Ohigashi 2, Michio Hoshi 1,3, Masaru Murai 2, Keiichi Uyemura 1, Takahito Yazaki 1,3,✉
PMCID: PMC5926297  PMID: 11123435

Abstract

Over the last few years, a conditionally replicating herpes simplex virus 1 (HSV‐1) vector, G207 has been used for the treatment of several malignant tumors. In this article we evaluate the antitumoral effect of G207 against prostate cancer in vitro and in vivo. The susceptibility of the human prostate cancer cell lines, DU145 and PC3 to G207 at a multiplicity of infection (MOI) of 0.1 was examined. In addition, the growth characteristics of G207 were assessed. Athymic mice with s.c. tumors were inoculated in vivo intraneoplastically with 1x107 plaque‐forming units (PFU) of G207. For the pathological analyses, s.c. tumors were stained with X‐gal. DU145 and PC3 were efficiently destroyed by G207 within 7 days. The viral yields of G207 increased time‐dependently. In vivo, the intraneoplastic inoculation of G207 induced a significant inhibition of the tumor growth. The mean tumor growth ratio was significantly inhibited in the G207‐treated tumors (DU145, P< 0.0001; PC3, P < 0.001 versus controls). In a pathological study, many lacZ‐positive cells were diffusely present in the G207‐treated tumors. G207 showed a significant antitumoral effect against human prostate cancer cell lines, and thus may be considered a useful agent for the treatment of prostate cancer.

Keywords: Prostate neoplasms, Herpes simplex virus, Oncolytic virus, Replication‐competent virus, Gene therapy

Full Text

The Full Text of this article is available as a PDF (3.1 MB).

REFERENCES

  • 1. ) Walker , J. R. , McGeagh , K. G. , Sundaresan , P. , Jorgensen , T. J. , Rabkin , S. D. and Martuza , R. L.Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207 . Hum. Gene Ther. , 10 , 2237 – 2243 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Mineta , T. , Rabkin , S. D. , Yazaki , T. , Hunter , W. D. and Martuza , R. L.Attenuated multi‐mutated herpes simplex virus‐1 for the treatment of malignant gliomas . Nat. Med. , 1 , 938 – 943 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Landis , S. H. , Murray , T. , Bolden , S. and Wingo , P. A.Cancer statistics, 1999 . CA Cancer J. Clin. , 49 , 8 – 31 31 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Paulson , D. F. , Moul , J. W. and Walther , P. J.Radical prostatectomy for clinical stage T1‐2N0M0 prostatic adenocarcinoma: long‐term results . J. Urol. , 144 , 1180 – 1184 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Bagshaw , M. A. , Cox , R. S. and Ramback , J. E.Radiation therapy for localized prostate cancer. Justification by long‐term follow‐up . Urol. Clin. North Am. , 17 , 787 – 802 ( 1990. ). [PubMed] [Google Scholar]
  • 6. ) Eastham , J. A. and Scardino , P. T.Radical prostatectomy . In “ Campbell's Urology ,” ed. Walsh P. C. , Retik A. B. , Vaughan E. D. and Wein A. J. , pp. 2547 – 2564 ( 1998. ). W. B. Saunders; , Philadelphia , PA . [Google Scholar]
  • 7. ) Herman , J. R. and Lerner , S. P.Current status of gene therapy for prostate and bladder cancer . Int. J. Urol. , 4 , 435 – 440 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Bischoff , J. R. , Kirn , D. H. , Williams , A. , Heise , C. , Horn , S. , Muna , M. , Ng , L. , Nye , J. A. , Sampson‐Johannes , A. , Fattaey , A. and McCormick , F.An adenovirus mutant that replicates selectively in p53‐deficient human tumor cells . Science , 274 , 373 – 376 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Heise , C. , Sampson‐Johannes , A. , Williams , A. , McCormick , F. , Von Hoff , D. D. and Kirn , D. H.ONYX‐015, an E1B gene‐attenuated adenovirus, causes tumor‐specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents . Nat. Med. , 3 , 639 – 645 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Bookstein , R. , MacGrogan , D. , Hilsenbeck , S. G. , Sharkey , F. and Allred , D. C.p53 is mutated in a subset of advanced‐stage prostate cancers . Cancer Res. , 53 , 3369 – 3373 ( 1993. ). [PubMed] [Google Scholar]
  • 11. ) Chou , J. , Kern , E. R. , Whitley , R. J. and Roizman , B.Mapping of herpes simplex virus‐1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture . Science , 250 , 1262 – 1266 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Chou , J. and Roizman , B.Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage . Proc. Natl. Acad. Sci. USA , 91 , 5247 – 5251 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. ) Goldstein , D. J. and Weller , S. K.Herpes simplex virus type 1‐induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant . J. Virol. , 62 , 196 – 205 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. ) Martuza , R. L. , Malick , A. , Markert , J. M. , Ruffner , K. L. and Coen , D. M.Experimental therapy of human glioma by means of a genetically engineered virus mutant . Science , 252 , 854 – 856 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Toda , M. , Rabkin , S. D. and Martuza , R. L.Treatment of human breast cancer in a brain metastatic model by G207, a replication‐competent multimutated herpes simplex virus 1 . Hum. Gene Ther. , 9 , 2177 – 2185 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Carew , J. F. , Kooby , D. A. , Halterman , M. W. , Federoff , H. J. and Fong , Y.Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207) . Hum. Gene Ther. , 10 , 1599 – 1606 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Yazaki , T. , Manz , H. J. , Rabkin , S. D. and Martuza , R. L.Treatment of human malignant meningiomas by G207, a replication‐competent multimutated herpes simplex virus 1 . Cancer Res. , 55 , 4752 – 4756 ( 1995. ). [PubMed] [Google Scholar]
  • 18. ) Sundaresan , P. , Hunter , W. D. , Martuza , R. L. and Rabkin , S. D.Attenuated, replication‐competent herpes simplex virus type 1 mutant G207: safety evaluation in mice . J. Virol. , 74 , 3832 – 3841 ( 2000. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. ) Hunter , W. D. , Martuza , R. L. , Feigenbaum , F. , Todo , T. , Mineta , T. , Yazaki , T. , Toda , M. , Newsome , J. T. , Platenberg , R. C. , Manz , H. J. and Rabkin , S. D.Attenuated, replication‐competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates . J. Virol. , 73 , 6319 – 6326 ( 1999. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. ) Chahlavi , A. , Rabkin , S. , Todo , T. , Sundaresan , P. and Martuza , R.Effect of prior exposure to herpes simplex virus 1 on viral vector‐mediated tumor therapy in immunocompetent mice . Gene Ther. , 6 , 1751 – 1758 ( 1999. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES